A randomised controlled trial to compare ocrelizumab or alemtuzumab wi
A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST)
What was tested
Treatment tested
- autologous hematopoietic stem cells
Compared with
- Alemtuzumab
CAMPATH-1 antigen inhibitor
- Ocrelizumab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
Time to treatment failure as assessed by failure of NEDA (no evidence of disease) activity during follow-up as defined by:
Other measures (1)
Efficacy:
Loading reviews and guidelines…
Related trials
- The HIt HArd and hiT Early in Multiple Sclerosis Trial
Phase 2 · Recruiting
Still running
- Effects of CLADribine tablets on the Immune Synapse, in Relapsing Mult
Phase 4 · Not yet recruiting
Still running
- No Evidence Of Disease Activity After Autologous Haematopoietic Stem C
Phase 2 · Stopped early
Stopped
- Cladribine Tablets Level of Response Predictors in Clinical Practice (
Running, not recruiting
Still running
- ADAs to Alemtuzumab
Completed
No results found
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY
Running, not recruiting
Still running
History
- In scope changed from true to false
Started
Aug 2019
Assembled by software from public sources.